However, the observed enhancement of VEGF and CD31 was suppressed by DOX and a higher dose of DOX-PRNP2 showed further inhibition of VEGF that indicated that PRNP2 increased the anti-tumor efficacy of doxycycline on colon cancer. Here, VEGFA is linked to colonic neoplasm.